课题基金 / 基金详情

CD6: Thymic Selection and Autoimmunity

CD6: Thymic Selection and Autoimmunity
CD6:胸腺选择和自身免疫
批准号:
6399112
负责人:
NORA SINGER
金额:
$33.98万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-01 至 2002-08-31

项目摘要

项目成果

NORA SINGER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
CD6 is a T-cell costimulatory molecule expressed on developing thymocytes and on mature T-cells. We hypothesize that a major role of CD6 is to costimulate thymocytes and mature T-cells during low functional avidity interactions with MHC/antigen complexes and to augment resistance of these cells to apoptosis. Mechanisms by which CD6 may contribute to autoimmunity include increased selection of self-reactive thymocytes, increased resistance of thymocytes and/or mature T-cells to apoptosis, and decreases in the stimulation threshold of mature T-cells to self-antigens. We will use complimentary "gain of function" and "loss of function" approaches, including mice bred either to lack or to overexpress CD6, in combination with antigen-specific TCR transgenic mice, thymic organ cultures, and specific soluble reagents which inhibit CD6/CD6 ligand interactions. Potential excesses in CD6-dependent costimulation could also occur if CD6 ligands are over-expressed during T-cell development and/or in tissues affected by autoimmunity. We have identified a new CD6 ligand that is expressed in the thymus, in skin and in synovium. We plan to clone this new CD6 ligand and to study its expression on thymic epithelium during T-cell development. Our specific aims are 1) to test the hypothesis that CD6-dependent costimulation to thymocytes increases functional avidity for AMC/antigen complexes and/or resistance to apoptosis; 2) to test the hypothesis that CD6-dependent costimulation to mature T-cells increases functional avidity and/or resistance to apoptosis; and 3) to clone the novel CD6 ligand and characterize its expression in the thymus. Our long-term goal is to understand the role of CD6 in immunity. One of the major problems in the treatment of autoimmunity is that current therapies reduce both autoimmunity and protective immunity simultaneously. We ultimately want to determine if inhibiting CD6/CD6L interactions can selectively inhibit reactivity with weaker self-antigens without compromising responses to stronger exogenous antigens that are important in innate immunity.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Mechanism by Which PF-3758309, a Pan Isoform Inhibitor of p21-Activated Kinases, Blocks Reactivation of HIV-1 Latency.
PF-3758309(p21 激活激酶的泛亚型抑制剂)阻止 HIV-1 潜伏期重新激活的机制。
DOI: 10.3390/biom13010100
发表时间: 2023-01-04
期刊: Biomolecules
影响因子: 5.5
作者: []
通讯作者:
CD6: Thymic Selection and Immune Response
  • 批准号:
    6625623
  • 项目类别:
  • 资助金额:
    $34.43万
  • 财政年份:
    2002
  • 负责人:
    NORA SINGER
  • 依托单位:
CD6: Thymic Selection and Immune Response
  • 批准号:
    6701298
  • 项目类别:
  • 资助金额:
    $33.91万
  • 财政年份:
    2002
  • 负责人:
    NORA SINGER
  • 依托单位:
CD6: Thymic Selection and Immune Response
  • 批准号:
    6847788
  • 项目类别:
  • 资助金额:
    $33.4万
  • 财政年份:
    2002
  • 负责人:
    NORA SINGER
  • 依托单位:
CD6: Thymic Selection and Immune Response
  • 批准号:
    7032230
  • 项目类别:
  • 资助金额:
    $32.59万
  • 财政年份:
    2002
  • 负责人:
    NORA SINGER
  • 依托单位:
海外基金